Olmesartán/Hidroclorotiazida Krka (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil and hydrochlorothiazide is used primarily for managing high blood pressure within the renin‑angiotensin‑aldosterone system pathway.

• Hypertension: Lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Heart failure adjunct: Assists in fluid management and blood‑pressure control when combined with other heart‑failure therapies.
• Diabetic nephropathy protection: Helps slow progression of kidney damage by controlling systemic pressure.
• Stroke‑risk reduction: Contributes to long‑term reduction of stroke incidence in hypertensive patients.
• Post‑myocardial‑infarction care: Supports blood‑pressure targets in patients recovering from heart attacks.

• Olmesartan medoxil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting natriuresis and diuresis. The combined actions reduce peripheral vascular resistance and plasma volume, resulting in lowered arterial pressure.

Olmesartan medoxil/hydrochlorothiazide is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Increased urination
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal discomfort

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Hyperkalemia or severe electrolyte imbalance
• Angio‑edema involving face, lips or airway
• Liver enzyme elevation
• Blood dyscrasias such as agranulocytosis

When prescribing Olmesartan medoxil/hydrochlorothiazide, clinicians should consider several safety aspects.

• Renal function monitoring: Assess baseline creatinine and eGFR, then periodically during therapy.
• Electrolyte surveillance: Check serum potassium and sodium levels, especially after dose changes.
• Pregnancy contraindication: Avoid use in pregnancy due to fetal toxicity.
• Drug‑interaction awareness: Review concomitant medications that affect potassium or renal function.
• Hypotension risk: Counsel patients to rise slowly from sitting or lying positions.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxil/hydrochlorothiazide may interact with several drug classes; careful review is essential.

Major Interactions (Avoid)

• Potassium‑sparing diuretics or supplements: May cause dangerous hyper‑kalemia.
• ACE inhibitors or ARBs combined with NSAIDs: Increases risk of renal impairment and hyper‑kalemia.
• Lithium: May increase lithium serum concentrations, risking toxicity.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): Can blunt antihypertensive effect and affect renal function.
• Antidiabetic agents: May require dose adjustments due to enhanced glucose‑lowering effect.
• Antimicrobials such as trimethoprim‑sulfamethoxazole: Can affect potassium balance.